biotech

Showing 15 posts of 861 posts found.

roche_glass_building

Tecentriq third time lucky after NICE nod in lung cancer

April 9, 2018
Sales and Marketing NICE, Roche, biotech, drugs, lung cancer, pharma, pharmaceutical, tecentriq

After having been knocked by twice by NICE, Roche has finally received a recommendation for Tecentriq’s second-line use in non-small …

Novartis CEO makes mark with $8.7bn AveXis acquisition

April 9, 2018
Sales and Marketing AveXis, Novartis, biotech, drugs, gene therapy, pharma, pharmaceutical

Vas Narasimhan’s first few moves as CEO of Novartis indicate that he is not afraid to take bold risks in …

roche_close

Roche suffers Ocrevus knockback by NICE

April 6, 2018
Medical Communications, Sales and Marketing Ocrevus, Roche, biotech, drugs, multiple sclerosis, pharma, pharmaceutical

Roche’s multiple sclerosis drug, Ocrevus (ocrelizumab), has been a big new growth driver for the company, especially in the US, …

china_block_001_takeda

Takeda move for Shire looks increasingly likely

April 6, 2018
Medical Communications, Sales and Marketing Japan, Shire, Takeda, UK, biotech, drugs, pharma, pharmaceutical

Takeda’s surprise announcement, just last week, that it was weighing up a move for Shire had some analysts sceptical about …

cystic_fibrosis_insider_interview

Transforming cystic fibrosis treatment

April 5, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Vertex, biotech, cystic fibrosis, drugs, pharma, pharmaceutical

Fred van Goor, Principle Research Fellow at Vertex Pharmaceuticals, discusses his history of work in cystic fibrosis and how the …

roche

Roche snaps up Inception neuroscience program

April 5, 2018
Sales and Marketing Pipeline Therapeutics, Roche, biotech, drugs, pharma, pharmaceutical

Back in 2014, Roche entered into strategic collaboration with Inception Sciences to look into the regenerative medicines space for multiple …

sugar

Obesity admissions double in four years

April 5, 2018
Medical Communications NHS, UK, biotech, drugs, pharma, pharmaceutical

New figures show that hospital admissions related to obesity have doubled over the last four years in the UK, placing …

lilly2_web

Lilly and Sigilon team up in $473m+ deal to ‘cure’ diabetes

April 5, 2018
Sales and Marketing Eli Lilly, Sigilon Therapeutics, biotech, drugs, pharma, pharmaceutical

Eli Lilly and Sigilon Therapeutics have announced a partnership that looks to break new ground in the management of type …

beam

Proton beam therapy finally arrives in UK

April 4, 2018
Medical Communications, Research and Development NHS, Proton beam therapy, biotech, drugs, pharma, pharmaceutical

28 years after the US first pioneered proton beam therapy at Loma Linda University Medical Center, the UK now has …

pfizer_chrome_plate

Pfizer running out of options for consumer business

April 4, 2018
Research and Development, Sales and Marketing P&G, Pfizer, Procter & Gamble, biotech, drugs, pharma, pharmaceutical

A surprise new name was thrown into the ring to take on Pfizer’s healthcare unit but speculation suggests that valuation …

shaking-hands-3091908_960_720

Ex-Kite execs form a CAR T rival

April 4, 2018
Research and Development, Sales and Marketing Allogene, Pfizer, biotech, drugs, pharma, pharmaceutical

After working to bring through Kite Pharma from the pre-clinical development stage to its final $12 billion acquisition by Gilead, …

One centre for cancer diagnoses trialled

April 3, 2018
Manufacturing and Production, Medical Communications, Sales and Marketing NHS, biotech, drugs, pharma, pharmaceutical

NHS England is trialling centres that should be able to provide rapid answers as to whether a patient has cancer …

Rumours Allergan is looking to offload $5bn women’s health unit

April 3, 2018
Manufacturing and Production, Sales and Marketing Allergan, Restasis, biotech, drugs, pharma, pharmaceutical

According to a piece by Bloomberg, Allergan is looking at options to divest its women’s health unit in a move …

celgene_1_02

Celgene’s COO heads to the exit

April 3, 2018
Manufacturing and Production, Medical Communications, Sales and Marketing Celgene, Mark Alles, Scott Smith, biotech, drugs, pharma, pharmaceutical

Celgene has had a rough six months, its share price since the beginning of October has dropped from $146 to …

The Gateway to Local Adoption Series

Latest content